[
  {
    "date": "2023-12-31",
    "symbol": "XTLB",
    "period": "FY",
    "cashandcashequivalents": 1401000,
    "currentmarketablesecurities": 605000,
    "currentprepaidexpenses": 40000,
    "currentassets": 2046000,
    "intangibleassetsotherthangoodwill": 380000,
    "noncurrentassets": 380000,
    "assets": 2426000,
    "tradeandothercurrentpayablestotradesuppliers": 206000,
    "issuedcapital": 14120000,
    "additionalpaidincapital": 146326000,
    "otherreserves": 20000,
    "retainedearnings": -158246000,
    "equity": 2220000,
    "equityandliabilities": 2426000,
    "parvaluepershare": 0.1,
    "numberofsharesauthorised": 1450000000,
    "numberofsharesissued": 544906149,
    "numberofsharesoutstanding": 544906149,
    "researchanddevelopmentexpense": 31000,
    "generalandadministrativeexpense": 734000,
    "profitlossfromoperatingactivities": -765000,
    "revaluationofmarketablesecurities": -1022000,
    "otherfinanceincome": 41000,
    "otherfinancecost": 36000,
    "financeincomecost": -1017000,
    "comprehensiveincome": -1782000,
    "basicearningslosspershare": -0.003,
    "dilutedearningslosspershare": -0.003,
    "weightedaverageshares": 544906149,
    "adjustedweightedaverageshares": 544906149,
    "profitloss": -1782000,
    "increasedecreasethroughsharebasedpaymenttransactions": 3000,
    "adjustmentstoreconcilenetlosstonetcashusedinoperatingactivities": 1075000,
    "cashflowsfromusedinoperatingactivities": -707000,
    "interestreceivedclassifiedasinvestingactivities": 41000,
    "cashflowsfromusedininvestingactivities": 41000,
    "increasedecreaseincashandcashequivalents": -666000,
    "effectofexchangeratechangesoncashandcashequivalents": -27000,
    "adjustmentsforsharebasedpayments": 3000,
    "adjustmentsforunrealisedforeignexchangelossesgains": 27000,
    "revenuefrominterest": 41000,
    "totalincomeandexpensesnotinvolvingcashflows": 1011000,
    "adjustmentsfordecreaseincreaseinprepaidexpenses": 45000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 19000,
    "adjustmentsforreconcileprofitloss": 64000,
    "cashflowsfromusedinoperations": 1075000,
    "disclosureofdetailedinformationaboutcurrenciescashandcashequivalentsdenominatedexplanatorytabletextblock": "Thecurrencies in which the cash and cash equivalents are denominated or linked to are:",
    "disclosureofdetailedinformationaboutmarketablesecuritiesexplanatorytabletextblock": "Changes in marketable securities for the years ended December 31, 2023, 2022 and 2021, were as follows:",
    "scheduleofcompositionofaccountspayabletextblock": "Composition:",
    "scheduleofcarryingamountofotheraccountspayabletextblock": "The carrying amount of accounts payable is denominated in the following currencies:",
    "disclosureofdetailedinformationaboutnumberandweightedaverageexercisepricesofshareoptionstabletextblock": "Movementsin the number of share options and their related weighted average exercise prices (in dollars) during the years ended December 31, 2023,2022 and 2021 are as follows:",
    "disclosureofdetailedinformationaboutexercisepriceandcontractuallifeforoptionsoutstandingtabletextblock": "Belowis information about the exercise price (in dollars) and the remaining contractual life (in years) for options outstanding at end ofyear:",
    "disclosureofdetailedinformationaboutoutstandingoptionstabletextblock": "Thetable below summarizes the outstanding options as of December 31, 2023 that have been granted to the Company’s executives, directorsand consultants",
    "scheduleoffairvalueforoptionsgrantedtabletextblock": "Thefair value for options granted in 2023 is estimated at the date of grant using a Black-Scholes model with the following weighted averageassumptions:",
    "disclosureofdetailedinformationaboutresearchanddevelopmentexpensestabletextblock": "Year    ended December 31,             2023      2022      2021             U.S.    dollars in thousands                                      Fees    related to service providers      31       30       30",
    "scheduleofprofitlossattributedtoordinaryshareholdersdilutedtabletexblock": "Profit(loss) attributed to ordinary shareholders (diluted)",
    "scheduleofweightedaveragenumberofordinarysharesdilutedtabletexblock": "Weighted-averagenumber of ordinary shares (diluted)",
    "averageforeignexchangerate": 3.627,
    "cashonhand": 133000,
    "shorttermdepositsclassifiedascashequivalents": 1268000,
    "financialassetsavailableforsale": 605000,
    "gainslossesonfairvalueonmarketablesecurities": -1022000,
    "currentprepaymentsandothercurrentassets": 29000,
    "governmentauthorities": 11000,
    "tradeandotherpayablestotradesuppliers": 1000,
    "accrualsclassifiedascurrent": 205000,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P6Y25D",
    "numberofoutstandingshareoptions": 12550000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.05,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 150000,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.01,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 12550000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.05,
    "exercisepriceofoutstandingshareoptions2019": 1.2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsposition": "Four Directors",
    "dateofgrantofsharebasedpaymentarrangement": "December 30, 2014",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingexerciseprice": 0.4325,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingvalue": 46000,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first",
    "feesrelatedtoserviceproviders": 31000,
    "wagesandsalaries": 107000,
    "expensefromsharebasedpaymenttransactionswithemployees": 3000,
    "patentsandfees": 94000,
    "directorsremunerationexpense": 60000,
    "rentandofficemaintenance": 12000,
    "insuranceexpense": 119000,
    "professionalfeesexpense": 330000,
    "otherexpensebynature": 9000,
    "sellinggeneralandadministrativeexpense": 734000,
    "financeexpensesrevaluationofmarketablesecurities": -1022000,
    "feeandcommissionexpense": 4000,
    "exchangedifferences": 32000,
    "financecosts": 1058000,
    "interestincomeondeposits": 41000,
    "financeincome": 41000,
    "financeincomeexpensesnet": -1017000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 240000,
    "employeebenefitsexpense": 243000,
    "numberofemployees": 8,
    "othercomprehensiveincomeattributabletononcontrollinginterests": -1782000,
    "issuedordinarysharesatjanuary1": 544906149,
    "weightedaveragenumberofordinarysharesbasic": 544906149,
    "othercomprehensiveincomebeforetax": -1782000,
    "weightedaveragenumberofordinarysharesdiluted": 544906149,
    "issuedandoutstandingrate": 0.446,
    "paymentofshareholders": 430000,
    "periodofclosingtransaction": "P3Y",
    "investmentincome": 1500000,
    "investorissued": 1500000,
    "priceperunit": 1,
    "adsissued": 1,
    "privateplacementwarrantsissued": 1,
    "warrantexercisedperiod": "P5Y",
    "percentageoffunctionalcurrency": 0.1,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 144000,
    "depositswithmaturity": "P3M",
    "borrowingsinterestrate": 0.0441,
    "percentageofholdingshare": 0.0104,
    "percentageofroyalties": 0.02,
    "percentageofsublicensefees": 0.15,
    "expirterm": "P11Y",
    "receivablesfromcontractswithcustomers": 8000000,
    "remainingliability": 380000,
    "intangibleassetotherinformationmaturitydate": "TheCompany exclusively licensed two families of patents relating to hCDR1:Oneexpired on September 22, 2022 (in the US. For all other countries, it expired on February 26, 2022) and the other expired on January14, 2024.",
    "assetsremainedamount": 380000,
    "licenseagreement": "Underthe license agreement, the Company is required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinicaltrial, $1 million upon FDA approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the EuropeanUnion’s Group of Five. In addition, the Company is required to pay 2%-3% royalties of annual net sales and sublicense fees of 15%-20%of whatever it receives from any sub-licensee.",
    "descriptionofwarrantsexercisable": "The warrants shall be exercisable six months following the issuance date and will expirefive and one-half years from the issuance date.",
    "informationabouthowexpectedvolatilitywasdeterminedshareoptionsgranted": "the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principalor most advantageous market in which it would transact and considers assumptions that market participants would use when pricing theasset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.",
    "remainingnumberofoptionsavailableforgrant": 17450000,
    "sharebasedpaymenttransactionstoemployeesandnonemployees": 3000,
    "taxeffectofimpairmentofgoodwill": 39000000,
    "deferredtaxassetscapitallosscarryforward": 23000000,
    "averageeffectivetaxrate": -0.23,
    "increasedecreaseindeferredtaxliabilityasset": 141000,
    "otherfeeandcommissionexpense": 15000,
    "administrativefeeexpense": 49000,
    "amountspayablerelatedpartytransactions": 32000,
    "percentageofshare": 0.0104,
    "currentmarketablesecuritie": 605000,
    "rentexpense": 11000,
    "tradeandotherreceivablesduefromrelatedparties": 3000,
    "entityregistrantname": "XTL BIOPHARMACEUTICALS LTD.",
    "tradingsymbol": "XTLB",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 544906149,
    "amendmentflag": "false",
    "entitycentralindexkey": 1023549,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36000",
    "entityincorporationstatecountrycode": "L3",
    "entityaddressaddressline1": "26 Ben-Gurion St",
    "entityaddresscityortown": "Ramat Gan",
    "entityaddresspostalzipcode": 5112001,
    "entityaddresscountry": "IL",
    "contactpersonnelname": "Shlomo Shalev",
    "cityareacode": 972,
    "localphonenumber": "3-6116600",
    "contactpersonnelfaxnumber": "+972-3-611-6605",
    "security12btitle": "American Depositary Shares, each representing one hundred Ordinary Shares, par value NIS 0.1",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentfinstmterrorcorrectionflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1057,
    "auditorname": "Somekh Chaikin",
    "auditorlocation": "Tel Aviv, Israel"
  },
  {
    "date": "2022-12-31",
    "symbol": "XTLB",
    "period": "FY",
    "cashandcashequivalents": 2094000,
    "currentmarketablesecurities": 1627000,
    "currentprepaidexpenses": 85000,
    "currentassets": 3806000,
    "intangibleassetsotherthangoodwill": 380000,
    "noncurrentassets": 380000,
    "assets": 4186000,
    "tradeandothercurrentpayablestotradesuppliers": 187000,
    "issuedcapital": 14120000,
    "additionalpaidincapital": 146326000,
    "otherreserves": 20000,
    "retainedearnings": -156467000,
    "equity": 20000,
    "equityandliabilities": 4186000,
    "parvaluepershare": 0.1,
    "numberofsharesauthorised": 1450000000,
    "numberofsharesissued": 544906149,
    "numberofsharesoutstanding": 544906149,
    "researchanddevelopmentexpense": 30000,
    "generalandadministrativeexpense": 850000,
    "profitlossfromoperatingactivities": -880000,
    "revaluationofwarrantstopurchaseads": 1054000,
    "revaluationofmarketablesecurities": -1531000,
    "otherfinanceincome": 36000,
    "otherfinancecost": 27000,
    "financeincomecost": -468000,
    "comprehensiveincomelossfortheyeardiluted": -1348000,
    "basicearningslosspershare": -0.002,
    "dilutedearningslosspershare": -0.002,
    "weightedaverageshares": 544906149,
    "adjustedweightedaverageshares": 544909149,
    "profitloss": -1348000,
    "increasedecreasethroughsharebasedpaymenttransactions": 14000,
    "adjustmentstoreconcilenetlosstonetcashusedinoperatingactivities": 447000,
    "cashflowsfromusedinoperatingactivities": -901000,
    "interestreceivedclassifiedasinvestingactivities": 36000,
    "cashflowsfromusedininvestingactivities": 36000,
    "increasedecreaseincashandcashequivalents": -865000,
    "effectofexchangeratechangesoncashandcashequivalents": -10000,
    "depreciationexpense": 1000,
    "revaluationofwarrantstopurchase": -1054000,
    "sharebasedpaymenttransactionstoemployeesandnonemployees": 14000,
    "gainsfromexchangeratedifferencesoncashandcashequivalents": -10000,
    "interestincome": 36000,
    "totalincomeandexpensesnotinvolvingcashflows": 466000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": 25000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -44000,
    "adjustmentsforreconcileprofitloss": -19000,
    "cashflowsfromusedinoperations": 447000,
    "disclosureoffinancialinstrumentsandfinancialriskmanagementexplanatorytextblock": "NOTE 4: FINANCIAL INSTRUMENTS AND FINANCIALRISK MANAGEMENT ",
    "disclosureofmarketablesecuritiesexplanatorytextblock": "NOTE 6: MARKETABLE SECURITIES – InterCureLtd ",
    "disclosureofprepaidexpensesexplanatorytabletextblock": "NOTE 7: PREPAID EXPENSES AND OTHE CURRENTASSETS ",
    "disclosureofotheraccountspayablesexplanatorytextblock": "NOTE 9: ACCOUNTS PAYABLE ",
    "warrantsatfairvalueofexplanatorytextblock": "NOTE 10: WARRANTS ",
    "descriptionofaccountingpolicyforbasisofpresentationoffinancialstatementspolicytextblock": "a.Basis of presentation of the consolidated financial statements: ",
    "descriptionofaccountingpolicyforconsolidatedfinancialstatementsexplanatorypolicytextblock": "b.Consolidated financial statements: ",
    "financeincomeandfinancecosts": "m.Finance income and finance costs: ",
    "disclosureofdetailedinformationaboutexchangerateexplanatorytabletextblock": "            Exchange rate       As of     of U.S. $ 1             NIS                     December 31, 2022      3.519       December 31, 2021      3.110    ",
    "disclosureofchangesinfinancialliabilitiesfromfinanceactivitiestextblock": "            Warrants             U.S. dollars in thousands                     Balance as of January 1, 2020      465       Revaluation during the year      2,172       Balance as of December 31, 2020      2,637       Revaluation during the year      (719)      Exercises during the year      (864)      Balance as of December 31, 2021      1,054       Revaluation during the year      (1,054)      Balance as of December 31, 2022      -   ",
    "disclosureofdetailedinformationaboutcashandcashequivalentsexplanatorytabletextblock": "            December 31,             2022      2021             U.S. dollars in thousands                            Cash in banks and on hand      1,413       599       Bank deposits with original maturities of three months or less*      681       2,370                                     2,094       2,969    ",
    "disclosureofdetailedinformationaboutcurrenciescashandcashequivalentsdenominatedexplanatorytabletextblock": "            December 31,             2022      2021             U.S. dollars in thousands                            U.S. dollars      2,009       2,807       NIS (not linked to the Israeli CPI)      85       162                                     2,094       2,969   ",
    "disclosureofdetailedinformationaboutmarketablesecuritiesexplanatorytabletextblock": "            December 31,             2022      2021      2020             U.S. dollars in thousands                                   Fair value opening balance      3,158       2,411       2,273       Changes in fair value during the year      (1,531)      747       138                                      Fair value closing balance      1,627       3,158       2,411   ",
    "disclosureofdetailedinformationaboutprepaidexpensesexplanatorytabletextblock": "            December 31,             2022      2021             U.S. dollars in thousands                            Government authorities (*)      14       16       Prepaid expenses      71       94              85       110    ",
    "scheduleofcompositionofaccountspayabletextblock": "            December 31,             2022      2021             U.S. dollars in thousands                            Trade payables      2       2       Accrued expenses      185       229                                     187       231    ",
    "scheduleofcarryingamountofotheraccountspayabletextblock": "            December 31,             2022      2021             U.S. dollars in thousands                            U.S. dollars      137       180       NIS (not linked to the Israeli CPI)      50       51                                     187       231   ",
    "scheduleofsharebasedpaymentawardstockwarrantsvaluationassumptionstabletextblock": "            December 31,             2021      2020                            Risk-free interest rate (1)      0.19%      0.12%      Expected volatility (2)      60.83-62.46%      68.59-69.23%      Contractual term life (in years) (3)      0.63-0.68       1.63-1.68       Dividend yield (4)      0%      0%   ",
    "disclosureofdetailedinformationaboutfairvalueoptionsgrantedforweightedaverageassumptionstabletextblock": "            2020                     Dividend yield      0%      Expected volatility      74.2%      Risk-free interest      0.67%      Expected life (years)      10    ",
    "disclosureofdetailedinformationaboutresearchanddevelopmentexpensestabletextblock": "            Year ended December 31,             2022      2021      2020             U.S. dollars in thousands                                   Fees related to service providers      30       30       38   ",
    "scheduleofprofitlossattributedtoordinaryshareholdersbasictabletextblock": "            2022      2021      2020             U.S. dollars in thousands       Total comprehensive income (loss) for the year      (1,348)      435       (2,954)   ",
    "scheduleofprofitlossattributedtoordinaryshareholdersdilutedtabletexblock": "            2022      2021      2020             U.S. dollars in thousands       Total comprehensive income (loss) for the year (basic)      (1,348)      435       (2,954)      Warrant revaluation income      -       (660)      -              (1,348)      (225)      (2,954)   ",
    "scheduleofweightedaveragenumberofordinarysharesdilutedtabletexblock": "            2022      2021      2020             Number of shares       Weighted-average number of ordinary shares (basic)      544,906,149       531,995,467       514,205,799       Effect of warrants      -       83,552,979       -                                      Weighted average number of ordinary shares (diluted)      544,906,149       615,548,446       514,205,799    ",
    "closingforeignexchangerate": 3.519,
    "propertyandequipmentusefullifepercentage": 0.33,
    "settlementsfairvaluemeasurementliabilities": 1054000,
    "cashonhand": 1413000,
    "shorttermdepositsclassifiedascashequivalents": 681000,
    "cashandcashequivalent": 85000,
    "currentinvestments": 1627000,
    "financialassetsavailableforsale": 3158000,
    "gainslossesonfairvalueonmarketablesecurities": -1531000,
    "governmentauthorities": 14000,
    "currentprepaidexpensesother": 71000,
    "tradeandotherpayablestotradesuppliers": 2000,
    "accrualsclassifiedascurrent": 185000,
    "othercurrentpayables": 50000,
    "numberofoutstandingshareoptionsinsharebasedpaymentarrangement": 12400000,
    "weightedaverageoutstandingexercisepriceofshareoptionsinsharebasedpaymentarrangement": 0.05,
    "numberofshareexercisableoptionsinsharebasedpaymentarrangement": 10733330,
    "weightedaverageexercisepriceofexercisableshareoptionsinsharebasedpaymentarrangement": 0.05,
    "numberofoutstandingshareoptionsinsharebasedpaymentarrangements": 12400000,
    "exercisepriceofshareoptionsoutstanding": 0.17,
    "weightedaverageremainingcontractuallifeofshareoptionsoutstanding": 2.66,
    "feesrelatedtoserviceproviders": 30000,
    "wagesandsalaries": 117000,
    "expensefromsharebasedpaymenttransactionswithemployees": 14000,
    "patentsandfees": 141000,
    "directorsremunerationexpense": 68000,
    "rentandofficemaintenance": 6000,
    "insuranceexpense": 202000,
    "professionalfeesexpense": 291000,
    "otherexpensebynature": 11000,
    "generalandadministrativeexpenses": 850000,
    "financeexpensesrevaluationofmarketablesecurities": -1531000,
    "feeandcommissionexpense": 11000,
    "exchangedifferences": 16000,
    "financecosts": 1558000,
    "revaluationofwarrantstopurchaseadss": 1054000,
    "interestincomeondeposits": 36000,
    "financeincome": 1090000,
    "financeincomeexpensesnet": -468000,
    "benefitspaidorpayable": 262000,
    "adjustmentsforsharebasedpayments": 14000,
    "employeebenefitsexpense": 276000,
    "numberofemployees": 8,
    "othercomprehensiveincomeattributabletononcontrollinginterests": -1348000,
    "issuedordinarysharesatjanuary1": 544906149,
    "weightedaveragenumberofordinarysharesbasic": 544906149,
    "othercomprehensiveincomebeforetax": -1348000,
    "comprehensiveincome": -1348000,
    "weightedaveragenumberofordinarysharesdiluted": 544906149,
    "descriptionofforeigncurrencyexchangeraterisk": "As of December 31, 2022, had theGroup’s functional currency strengthened by 10% against the NIS with all other variables remaining constant, loss for the year wouldhave been $152 thousand higher (2021 - profit would have been $328 thousand higher; 2020 - loss approximately $242 thousand lower), mainlyas a result of exchange rate changes on translation of other accounts receivable and exchange rate changes on NIS-denominated cash andcash equivalents. ",
    "depositswithmaturity": "three months",
    "borrowingsinterestrate": 0.045,
    "percentageofholdingshare": 0.010400000000000001,
    "licenseagreement": "Under the license agreement, the Companyis required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical trial, $1 million upon FDA approvalto market in the U.S., and $250,000 for marketing approval in each of China and three of the European Union’s Group of Five. Inaddition, the Company is required to pay 2%-3% royalties of annual net sales and sublicense fees of 15%-20% of whatever it receives fromany sub-licensee.",
    "expirterm": 11,
    "receivablesfromcontractswithcustomers": 8000000,
    "remainingliability": 380000,
    "intangibleassetotherinformationmaturitydate": "The Company exclusively licensed twofamilies of patents relating to hCDR1: ",
    "assetsremainedamount": 380000,
    "descriptionofwarrantsexercisable": "The warrants shall be exercisable six months following the issuance date and will expire five and one-half yearsfrom the issuance date.",
    "informationabouthowexpectedvolatilitywasdeterminedshareoptionsgranted": "the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal ormost advantageous market in which it would transact and considers assumptions that market participants would use when pricing the assetor liability, such as inherent risk, transfer restrictions and risk of nonperformance.",
    "ordinarysharesdescription": "The Company’s Ordinary shares of NIS 0.1 par value are traded on the TASE. The Company’sADSs are listed for trading on the Nasdaq Capital Market in the U.S. Each ADS consist of 100 Company’s Ordinary shares.",
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 17600000,
    "unvestedoptions": 1000,
    "weightedaveragedurationofdefinedbenefitobligation2019": 0.5,
    "taxeffectofimpairmentofgoodwill": 39000000,
    "deferredtaxassetscapitallosscarryforward": 24000000,
    "averageeffectivetaxrate": 0.23,
    "increasedecreaseindeferredtaxliabilityasset": 86000,
    "otherfeeandcommissionexpense": 15000,
    "administrativefeeexpense": 53000,
    "amountspayablerelatedpartytransactions": 34000,
    "percentageofshare": 0.010400000000000001,
    "currentmarketablesecuritie": 1627000,
    "rentexpense": 5000,
    "revenuethatwasincludedincontractliabilitybalanceatbeginningofperiod": 2000,
    "entityregistrantname": "XTL BIOPHARMACEUTICALS LTD.",
    "tradingsymbol": "XTLB",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 544906149,
    "amendmentflag": "false",
    "entitycentralindexkey": 1023549,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36000",
    "entityincorporationstatecountrycode": "Israel",
    "entityaddressaddressline1": "5 Badner St.",
    "entityaddresscityortown": "Ramat Gan",
    "entityaddressaddressline2": "Ramat Gan",
    "entityaddresspostalzipcode": 5218102,
    "entityaddresscountry": "Israel",
    "contactpersonnelname": "Shlomo Shalev",
    "localphonenumber": "3-6116600",
    "cityareacode": 972,
    "security12btitle": "American Depositary Shares, each representing one hundred Ordinary Shares, par value NIS 0.1",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1057,
    "auditorname": "Somekh Chaikin",
    "auditorlocation": "Tel Aviv, Israel"
  },
  {
    "date": "2021-12-31",
    "symbol": "XTLB",
    "period": "FY",
    "cashandcashequivalents": 2969000,
    "currentmarketablesecurities": 3158000,
    "othercurrentreceivables": 110000,
    "currentassets": 6237000,
    "othernoncurrentfinancialassets": 1000,
    "intangibleassetsotherthangoodwill": 380000,
    "noncurrentassets": 381000,
    "assets": 6618000,
    "tradeandothercurrentpayablestotradesuppliers": 231000,
    "warrants": 650000,
    "issuedcapital": 14120000,
    "additionalpaidincapital": 146326000,
    "otherreserves": 20000,
    "retainedearnings": -155133000,
    "equity": 20000,
    "equityandliabilities": 6618000,
    "parvaluepershare": 0.1,
    "numberofsharesauthorised": 1450000000,
    "numberofsharesissued": 544906149,
    "numberofsharesoutstanding": 544906149,
    "researchanddevelopmentexpense": 30000,
    "generalandadministrativeexpense": 1001000,
    "profitlossfromoperatingactivities": -1031000,
    "revaluationofwarrantstopurchaseads": 719000,
    "revaluationofmarketablesecurities": 747000,
    "otherfinanceincome": 21000,
    "otherfinancecost": 21000,
    "financeincomecost": 1466000,
    "comprehensiveincomelossfortheyearbasic": 435000,
    "comprehensiveincomelossfortheyeardiluted": -225000,
    "basicearningslosspershare": 0.001,
    "weightedaverageshares": 531995467,
    "adjustedweightedaverageshares": 615548446,
    "profitloss": 435000,
    "increasedecreasethroughexerciseofwarrantsequity": 1249000,
    "increasedecreasethroughsharebasedpaymenttransactions": 37000,
    "adjustmentstoreconcilenetlosstonetcashusedinoperatingactivities": -1484000,
    "cashflowsfromusedinoperatingactivities": -1049000,
    "interestreceivedclassifiedasinvestingactivities": 8000,
    "cashflowsfromusedininvestingactivities": 8000,
    "proceedsfromexerciseofwarrants": 385000,
    "cashflowsfromusedinfinancingactivities": 385000,
    "increasedecreaseincashandcashequivalents": -656000,
    "effectofexchangeratechangesoncashandcashequivalents": -6000,
    "depreciationexpense": 1000,
    "revaluationofwarrantstopurchase": -719000,
    "sharebasedpaymenttransactionstoemployeesandnonemployees": 37000,
    "gainsfromexchangeratedifferencesoncashandcashequivalents": -6000,
    "interestincome": 8000,
    "totalincomeandexpensesnotinvolvingcashflows": -1430000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -31000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -23000,
    "adjustmentsforreconcileprofitloss": -54000,
    "cashflowsfromusedinoperations": -1484000,
    "proceedsfromexerciseofoptions": 864000,
    "disclosureoffinancialinstrumentsandfinancialriskmanagementexplanatorytextblock": "NOTE 4: FINANCIAL INSTRUMENTS AND FINANCIALRISK MANAGEMENT ",
    "disclosureofmarketablesecuritiesexplanatorytextblock": "NOTE 6: MARKETABLE SECURITIES – InterCureLtd ",
    "disclosureofprepaidexpensesexplanatorytabletextblock": "NOTE 7: PREPAID EXPENSES AND OTHE CURRENTASSETS ",
    "disclosureofotheraccountspayablesexplanatorytextblock": "NOTE 9: ACCOUNTS PAYABLE ",
    "warrantsatfairvalueofexplanatorytextblock": "NOTE 11: WARRANTS ",
    "sharecapitalreservesandretainedearnings": "NOTE 13: SHARE CAPITAL, RESERVES AND RETAINEDEARNINGS  ",
    "descriptionofaccountingpolicyforbasisofpresentationoffinancialstatementspolicytextblock": "a.Basis of presentation of the consolidated financial statements: ",
    "descriptionofaccountingpolicyforconsolidatedfinancialstatementsexplanatorypolicytextblock": "b.Consolidated financial statements: ",
    "disclosureofdetailedinformationaboutexchangerateexplanatorytabletextblock": "            Exchange rate       As of     of U.S. $ 1             NIS                     December 31, 2021      3.110       December 31, 2020      3.215    ",
    "disclosureofchangesinfinancialliabilitiesfromfinanceactivitiestextblock": "            Warrants             U.S. dollars in thousands                     Balance as of January 1, 2019      1,049       Revaluation during the year      (584)      Balance as of December 31, 2019      465       Revaluation during the year      2,172       Balance as of December 31, 2020      2,637       Revaluation during the year      (719)      Exercises during the year      (864)      Balance as of December 31, 2021      1,054   ",
    "disclosureofdetailedinformationaboutcashandcashequivalentsexplanatorytabletextblock": "            December 31,             2021      2020             U.S. dollars in thousands                            Cash in banks and on hand      599       361       Bank deposits with original maturities of three months or less*      2,370       3,270                                     2,969       3,631    ",
    "disclosureofdetailedinformationaboutcurrenciescashandcashequivalentsdenominatedexplanatorytabletextblock": "            December 31,             2021      2020             U.S. dollars in thousands                            U.S. dollars      2,807       3,538       NIS (not linked to the Israeli CPI)      162       93                                     2,969       3,631   ",
    "disclosureofdetailedinformationaboutmarketablesecuritiesexplanatorytabletextblock": "            December 31,             2021      2020      2019             U.S. dollars in thousands                                   Fair value opening balance      2,411       2,273       2,847       Changes in fair value during the year      747       138       (574)                                     Fair value closing balance      3,158       2,411       2,273   ",
    "disclosureofdetailedinformationaboutprepaidexpensesexplanatorytabletextblock": "            December 31,             2021      2020             U.S. dollars in thousands                            Government authorities (*)      16       13       Prepaid expenses      94       66                                     110       79    ",
    "scheduleofcompositionofaccountspayabletextblock": "            December 31,             2021      2020             U.S. dollars in thousands                            Trade payables      2       2       Accrued expenses      229       252                                     231       254    ",
    "scheduleofcarryingamountofotheraccountspayabletextblock": "            December 31,             2021      2020             U.S. dollars in thousands                            U.S. dollars      180       160       NIS (not linked to the Israeli CPI)      51       94                                     231       254   ",
    "scheduleofsharebasedpaymentawardstockwarrantsvaluationassumptionstabletextblock": "            December 31,             2021      2020      2019                                   Risk-free interest rate (1)      0.19%      0.12%      1.6%      Expected volatility (2)      60.83-62.46%      68.59-69.23%      52.53-52.62%      Contractual term life (in years) (3)      0.63-0.68       1.63-1.68       2.63-2.68       Dividend yield (4)      0%      0%      0%   ",
    "disclosureofdetailedinformationaboutfairvalueoptionsgrantedforweightedaverageassumptionstabletextblock": "            2020                     Dividend yield      0%      Expected volatility      74.2%      Risk-free interest      0.67%      Expected life (years)      10    ",
    "disclosureofdetailedinformationaboutresearchanddevelopmentexpensestabletextblock": "            Year ended December 31,             2021      2020      2019             U.S. dollars in thousands                     Fees related to service providers      30       38       35   ",
    "scheduleofprofitlossattributedtoordinaryshareholdersbasictabletextblock": "            2021      2020      2019             U.S. dollars in thousands       Total comprehensive income (loss) for the year      435       (2,954)      (763)   ",
    "scheduleofprofitlossattributedtoordinaryshareholdersdilutedtabletexblock": "            2021      2020      2019             U.S. dollars in thousands       Total comprehensive income (loss) for the year (basic)      435       (2,954)      (763)      Warrant revaluation income      (660)      -       -              (225)      (2,954)      (763)   ",
    "scheduleofweightedaveragenumberofordinarysharesdilutedtabletexblock": "            2021      2020      2019             Number of shares       Weighted-average number of ordinary shares (basic)      531,995,467       514,205,799       514,205,799       Effect of warrants      83,552,979       -       -                                      Weighted average number of  ordinary shares (diluted)      615,548,446       514,205,799       514,205,799    ",
    "closingforeignexchangerate": 3.11,
    "propertyandequipmentusefullifepercentage": 0.33,
    "financialliabilities": 1054000,
    "settlementsfairvaluemeasurementliabilities": 719000,
    "exercisesduringtheyear": 864000,
    "cashonhand": 599000,
    "shorttermdepositsclassifiedascashequivalents": 2370000,
    "cashandcashequivalent": 162000,
    "currentinvestments": 3158000,
    "financialassetsavailableforsale": 2411000,
    "gainslossesonfairvalueonmarketablesecurities": 747000,
    "governmentauthorities": 16000,
    "currentprepaidexpensesother": 94000,
    "currentprepaidexpenses": 110000,
    "tradeandotherpayablestotradesuppliers": 2000,
    "accrualsclassifiedascurrent": 229000,
    "othercurrentpayables": 51000,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0067,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.742,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 10,
    "warrantsoutstandingtopurchaseadss": 1847500,
    "full_exercisepriceofoutstandingshareoptions2019": 184750000,
    "issuancedate": "March 7, 2017",
    "valueinusdperwarrant": 0.77,
    "exercisepriceinusdperwarrant": 2.3,
    "expirationdatewarrants": "September 6, 2022",
    "numberofwarrantsoutstanding": 1197500,
    "valueinusdperwarrantoutstanding": 0.77,
    "numberofwarrantsexercised": -202500,
    "valueinusdperwarrantexercised": 2.94,
    "numberofoutstandingshareoptionsinsharebasedpaymentarrangement": 12400000,
    "weightedaverageoutstandingexercisepriceofshareoptionsinsharebasedpaymentarrangement": 0.05,
    "numberofshareexpiredoptionsinsharebasedpaymentarrangement": -3433331,
    "weightedaverageexercisepriceofshareexpiredoptionsinsharebasedpaymentarrangement": 0.16,
    "numberofshareforfeitedoptionsinsharebasedpaymentarrangement": -366669,
    "weightedaverageexercisepriceofshareforfeitedoptionsinsharebasedpaymentarrangement": 0.08,
    "numberofshareexercisableoptionsinsharebasedpaymentarrangement": 7399998,
    "weightedaverageexercisepriceofexercisableshareoptionsinsharebasedpaymentarrangement": 0.07,
    "numberofoutstandingshareoptionsinsharebasedpaymentarrangements": 12400000,
    "exercisepriceofshareoptionsoutstanding": 0.17,
    "weightedaverageremainingcontractuallifeofshareoptionsoutstanding": 3.66,
    "optionsoutstanding": 12400000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsposition": "Chief Executive Officer (new)",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantdate": "July 7, 2020",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingexerciseprice": 0.09,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingvalue": 103000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandinginperioddescription": "12 equal portions each quarter over a period of 3 years from the grant date",
    "feesrelatedtoserviceproviders": 30000,
    "wagesandsalaries": 123000,
    "expensefromsharebasedpaymenttransactionswithemployees": 37000,
    "patentsandfees": 137000,
    "directorsremunerationexpense": 64000,
    "travelexpense": 3000,
    "rentandofficemaintenance": 15000,
    "insuranceexpense": 229000,
    "professionalfeesexpense": 381000,
    "otherexpensebynature": 12000,
    "generalandadministrativeexpenses": 1001000,
    "feeandcommissionexpense": 21000,
    "financecosts": 21000,
    "revaluationofwarrantstopurchaseadss": 719000,
    "revaluationmarketablesecurities": 747000,
    "interestincomeondeposits": 8000,
    "gainonexchangedifferencesontranslationnetoftax": 13000,
    "financeincome": 1487000,
    "financeincomeexpensesnet": 1466000,
    "accountingprofit": 435000,
    "taxeffectoftaxlosses": 100000,
    "taxeffectofexpensesnotdeductibleindeterminingtaxableprofittaxloss": 515000,
    "taxeffectfromchangeintaxrate": -615000,
    "benefitspaidorpayable": 239000,
    "adjustmentsforsharebasedpayments": 37000,
    "employeebenefitsexpense": 276000,
    "numberofemployees": 8,
    "othercomprehensiveincomeattributabletononcontrollinginterests": 435000,
    "issuedordinarysharesatjanuary1": 514205799,
    "issued": 776713,
    "weightedaveragenumberofordinarysharesbasic": 531995467,
    "othercomprehensiveincomebeforetax": 435000,
    "warrantrevaluationincome": -660000,
    "comprehensiveincome": -225000,
    "effectofwarrants": 83552979,
    "weightedaveragenumberofordinarysharesdiluted": 615548446,
    "descriptionofforeigncurrencyexchangeraterisk": "As of December 31, 2021, had theGroup’s functional currency strengthened by 10% against the NIS with all other variables remaining constant, post-tax profit forthe year would have been $328 thousand higher (2020 - loss approximately $242 thousand lower; 2019 - loss approximately $233 thousandlower), mainly as a result of exchange rate changes on translation of other accounts receivable and exchange rate changes on NIS-denominatedcash and cash equivalents. ",
    "depositswithmaturity": "three months",
    "borrowingsinterestrate": 0.016,
    "percentageofholdingshare": 0.0111,
    "licenseagreement": "Under the license agreement, we arerequired to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical trial, $1 million upon FDA approvalto market in the U.S., and $250,000 for marketing approval in each of China and three of the European Union’s Group of Five. Inaddition, we are required to pay 2-3% royalties of annual net sales and sublicense fees of 15-20% of whatever we receive from any sub-licensee.",
    "expirterm": 11,
    "receivablesfromcontractswithcustomers": 8000000,
    "remainingliability": 127000,
    "intangibleassetotherinformationmaturitydate": "The Company exclusively licensed twofamilies of patents relating to hCDR1: ",
    "assetsremainedamount": 380,
    "descriptionofwarrantsexercisable": "The warrants shall be exercisable six months following the issuance date and will expire five andone-half years from the issuance date.",
    "informationabouthowexpectedvolatilitywasdeterminedshareoptionsgranted": "If the change in standarddeviation for that warrants shifted +/- 5%, the impact on the 2018 profit or loss would be $162thousands and $159 thousands, respectively. The higher the standard deviation, the higher the fair value.",
    "ordinarysharesdescription": "The Company’s Ordinary shares of NIS 0.1 are traded on the TASE. The Company’s ADSs arelisted for trading on the Nasdaq Capital Market in the U.S. The share price was NIS 0.086 (USD 0.0277) as of December 31, 2021.",
    "unvestedoptions": 15000,
    "weightedaveragedurationofdefinedbenefitobligation2019": 1.5,
    "taxeffectofimpairmentofgoodwill": 44000000,
    "amountspayablerelatedpartytransactions": 30000,
    "currentmarketablesecuritie": 3158000,
    "rentexpense": 14000,
    "percentageofshare": 0.0111,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 12400000,
    "eachwarrantisexercisabletoshares": 100,
    "optionexercisedinsharebasedpaymentarrangement": 12400000,
    "numberofsharewarrantsexercisedinsharebasedpaymentarrangement": 184750000,
    "entityregistrantname": "XTL BIOPHARMACEUTICALS LTD.",
    "tradingsymbol": "XTLB",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 544906149,
    "amendmentflag": "false",
    "entitycentralindexkey": 1023549,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36000",
    "entityincorporationstatecountrycode": "Israel",
    "entityaddressaddressline1": "5 Badner St.",
    "entityaddressaddressline2": "Ramat Gan",
    "entityaddresscityortown": "Ramat Gan",
    "entityaddresspostalzipcode": 4365603,
    "entityaddresscountry": "Israel",
    "contactpersonnelname": "Shlomo Shalev",
    "security12btitle": "American Depositary Shares, each representing  one hundred Ordinary Shares, par value NIS 0.1",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1309,
    "auditorlocation": "Tel-Aviv, Israel",
    "auditorname": "Kesselman & Kesselman",
    "cityareacode": 972,
    "localphonenumber": "3-6116600"
  },
  {
    "date": "2020-12-31",
    "symbol": "XTLB",
    "period": "FY",
    "cashandcashequivalents": 3631000,
    "currentmarketablesecurities": 2411000,
    "othercurrentreceivables": 79000,
    "currentassets": 6121000,
    "othernoncurrentfinancialassets": 2000,
    "intangibleassetsotherthangoodwill": 380000,
    "noncurrentassets": 382000,
    "assets": 6503000,
    "tradeandothercurrentpayablestotradesuppliers": 254000,
    "issuedcapital": 13182000,
    "additionalpaidincapital": 147708000,
    "otherreserves": 20000,
    "retainedearnings": -154661000,
    "equity": 20000,
    "equityandliabilities": 6503000,
    "parvaluepershare": 0.1,
    "numberofsharesauthorised": 1450000000000,
    "numberofsharesissued": 514205799000,
    "numberofsharesoutstanding": 514205799000,
    "researchanddevelopmentexpense": 38000,
    "generalandadministrativeexpense": 910000,
    "profitlossfromoperatingactivities": -948000,
    "revaluationofmarketablesecurities": 138000,
    "otherfinanceincome": 45000,
    "otherfinancecost": 17000,
    "financeincomecost": 166000,
    "profitloss": -782000,
    "basicanddilutedearningslosspershare": -0.002,
    "weightedaverageshares": 514205799,
    "increasedecreasethroughsharebasedpaymenttransactions": 51000,
    "adjustmentstoreconcilenetlosstonetcashusedinoperatingactivities": -68000,
    "cashflowsfromusedinoperatingactivities": -850000,
    "interestreceivedclassifiedasinvestingactivities": 33000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 1000,
    "cashflowsfromusedininvestingactivities": 32000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -818000,
    "effectofexchangeratechangesoncashandcashequivalents": -6000,
    "depreciationexpense": 1000,
    "sharebasedpaymenttransactionstoemployeesandnonemployees": 51000,
    "gainsfromexchangeratedifferencesoncashandcashequivalents": -6000,
    "interestreceivedclassifiedasoperatingactivities": -33000,
    "totalincomeandexpensesnotinvolvingcashflows": -113000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": 23000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 22000,
    "adjustmentsforreconcileprofitloss": 45000,
    "cashflowsfromusedinoperations": -68000,
    "closingforeignexchangerate": 3.215,
    "propertyandequipmentusefullifepercentage": 0.33,
    "cash": 361000,
    "shorttermdepositsclassifiedascashequivalents": 3270000,
    "cashandcashequivalent": 93000,
    "marketablesecuritiescurrent": 2411000,
    "financialassetsavailableforsale": 2273000,
    "gainslossesonfairvalueonmarketablesecurities": 138000,
    "governmentauthorities": 13000,
    "currentprepaidexpensesother": 66000,
    "currentprepaidexpenses": 79000,
    "tradeandotherpayablestotradesuppliers": 2000,
    "accrualsclassifiedascurrent": 252000,
    "othercurrentpayables": 94000,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0067,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.742,
    "numberofwarrantsoutstanding": 2450000,
    "numberofsharesexercisable": 245000000,
    "warrantsissuancedate": "2017-03-07",
    "warrantsexerciseprice": 2.3,
    "warrantsexpirationdate": "2022-09-06",
    "numberofoutstandingshareoptionsinsharebasedpaymentarrangement": 16200000,
    "weightedaverageoutstandingexercisepriceofshareoptionsinsharebasedpaymentarrangement": 0.07,
    "numberofsharegrantedoptionsinsharebasedpaymentarrangement": 20000000,
    "weightedaverageexercisepriceofsharegrantedoptionsinsharebasedpaymentarrangement": 0.03,
    "numberofshareforfeitedoptionsinsharebasedpaymentarrangement": -10000000,
    "weightedaverageexercisepriceofshareforfeitedoptionsinsharebasedpaymentarrangement": 0.03,
    "numberofshareexercisableoptionsinsharebasedpaymentarrangement": 7699997,
    "weightedaverageexercisepriceofexercisableshareoptionsinsharebasedpaymentarrangement": 0.13,
    "numberofoutstandingshareoptionsinsharebasedpaymentarrangements": 16200000,
    "exercisepriceofshareoptionsoutstanding": 1.6,
    "weightedaverageremainingcontractuallifeofshareoptionsoutstanding": "P4Y43D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 16200000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantdate": "2020-07-07",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingexerciseprice": 0.09,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingvalue": 103000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandinginperioddescription": "12 equal portions each quarter over a period of 3 years from the grant date",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P10Y",
    "feesrelatedtoserviceproviders": 38000,
    "wagesandsalaries": 122000,
    "expensefromsharebasedpaymenttransactionswithemployees": 51000,
    "patentsandfees": 150000,
    "directorsremunerationexpense": 109000,
    "travelexpense": 4000,
    "rentandofficemaintenance": 42000,
    "insuranceexpense": 151000,
    "professionalfeesexpense": 266000,
    "otherexpensebynature": 15000,
    "feeandcommissionexpense": 17000,
    "financecosts": 17000,
    "revaluationmarketablesecurities": 138000,
    "interestincomeondeposits": 33000,
    "gainonexchangedifferencesontranslationnetoftax": 12000,
    "financeincome": 183000,
    "accountingprofit": -782000,
    "taxeffectoftaxlosses": -180000,
    "taxeffectofexpensesnotdeductibleindeterminingtaxableprofittaxloss": -79000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 1000,
    "taxeffectfromchangeintaxrate": 258000,
    "benefitspaidorpayable": 276000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 2000,
    "adjustmentsforsharebasedpayments": 51000,
    "employeebenefitsexpense": 329000,
    "numberofemployees": 8,
    "descriptionofforeigncurrencyexchangeraterisk": "As of December 31, 2020, had the Group&#x2019;s functional currency strengthened by 10% against the NIS with all other variables remaining constant, post-tax loss for the year would have been $242 thousand lower (2019 - loss approximately $233 thousand lower; 2018 - profit approximately $289 thousand higher), mainly as a result of exchange rate changes on translation of other accounts receivable and exchange rate changes on NIS-denominated cash and cash equivalents.",
    "depositswithmaturity": "P3M",
    "borrowingsinterestrate": 0.0045,
    "percentageofholdingshare": 0.0176,
    "intangibleassetsofroyaltiesexpenses": 127000,
    "intangibleassetotherinformationmaturitydate": "The Company exclusively licensed two families of patents relating to hCDR1: One expires on September 22, 2022 and the other expires on January 14, 2024.",
    "postemploymentbenefitexpensedefinedcontributionplans": 2000,
    "descriptionofwarrantsexercisable": "The warrants shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date.",
    "informationabouthowexpectedvolatilitywasdeterminedshareoptionsgranted": "If the change in standard deviation for that warrants shifted +/- 5%, the impact on the 2018 profit or loss would be $162 thousands and $159 thousands, respectively. The higher the standard deviation, the higher the fair value.",
    "changesineffectivedateofsharesdescription": "The Company&#x2019;s Ordinary shares of NIS 0.1 are traded on the TASE. The Company&#x2019;s ADSs are listed for trading on the Nasdaq Capital Market in the U.S. The share price was NIS 0.098 (USD 0.0305) as of December 31, 2020.",
    "applicabletaxrate": 0.23,
    "taxeffectofimpairmentofgoodwill": 41000000,
    "amountspayablerelatedpartytransactions": 52000,
    "currentmarketablesecuritie": 2411000,
    "rentexpense": 20000,
    "proportionofownershipinterestinintercureltd": 0.0176,
    "optionexercisedinsharebasedpaymentarrangement": 16200000,
    "numberofsharewarrantsexercisedinsharebasedpaymentarrangement": 245000000,
    "entityregistrantname": "XTL BIOPHARMACEUTICALS LTD",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 514205799,
    "amendmentflag": "false",
    "entitycentralindexkey": 1023549,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "documentannualreport": "true",
    "documentshellcompanyreport": "false",
    "documenttransitionreport": "false",
    "entityincorporationstatecountrycode": "L3",
    "entityinteractivedatacurrent": "Yes"
  },
  {
    "date": "2019-12-31",
    "symbol": "XTLB",
    "period": "FY",
    "entityregistrantname": "XTL BIOPHARMACEUTICALS LTD",
    "entitycentralindexkey": 1023549,
    "documenttype": "20-F",
    "documentperiodenddate": "2019-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 514205799,
    "entityinteractivedatacurrent": "Yes",
    "entityincorporationstatecountrycode": "L3",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "cashandcashequivalents": 99000,
    "currentmarketablesecurities": 2273000,
    "othercurrentreceivables": 102000,
    "currentassets": 6830000,
    "othernoncurrentfinancialassets": 2000,
    "intangibleassetsotherthangoodwill": 380000,
    "assets": 7212000,
    "tradeandothercurrentpayablestotradesuppliers": 232000,
    "issuedcapital": 13182000,
    "sharepremium": 147708000,
    "otherreserves": 20000,
    "retainedearnings": -153930000,
    "equity": 20000,
    "equityandliabilities": 7212000,
    "parvaluepershare": 0.1,
    "numberofsharesauthorised": 1450000000,
    "numberofsharesissued": 514205799,
    "numberofsharesoutstanding": 514205799,
    "researchanddevelopmentexpense": 35000,
    "generalandadministrativeexpense": 807000,
    "profitlossfromoperatingactivities": -842000,
    "revaluationofmarketablesecurities": -574000,
    "otherfinanceincome": 98000,
    "otherfinancecost": 29000,
    "financeincomecost": -505000,
    "profitloss": -1347000,
    "comprehensiveincome": -1347000,
    "profitlossattributabletononcontrollinginterests": -1347000,
    "comprehensiveincomeattributabletoownersofparent": -1347000,
    "basicanddilutedearningslosspershare": -0.003,
    "weightedaverageshares": 514205799,
    "increasedecreasethroughsharebasedpaymenttransactions": 5000,
    "adjustmentstoreconcilenetlosstonetcashusedinoperatingactivities": 439000,
    "cashflowsfromusedinoperatingactivities": -908000,
    "repaymentofshort-termbankdeposit": 2020000,
    "interestreceivedclassifiedasinvestingactivities": 93000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 2000,
    "cashflowsfromusedininvestingactivities": 2111000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 1203000,
    "effectofexchangeratechangesoncashandcashequivalents": -3000,
    "sharebasedpaymenttransactionstoemployeesandnonemployees": 5000,
    "gainsfromexchangeratedifferencesoncashandcashequivalents": -3000,
    "interestreceivedclassifiedasoperatingactivities": -93000,
    "totalincomeandexpensesnotinvolvingcashflows": 489000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -29000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -21000,
    "adjustmentsforreconcileprofitloss": -50000,
    "cashflowsfromusedinoperations": 439000,
    "closingforeignexchangerate": 3.456,
    "propertyandequipmentusefullifepercentage": 0.33,
    "descriptionofforeigncurrencyexchangeraterisk": "The Group’s functional currency strengthened by 10% against the NIS with all other variables remaining constant, post-tax loss for the year would have been $233 thousand lower (2018 - profit approximately $289 thousand higher; 2017 - loss approximately $38 thousand lower), mainly as a result of exchange rate changes on translation",
    "cash": 277000,
    "shorttermdepositsclassifiedascashequivalents": 4178000,
    "borrowingsinterestrate": 0.0179,
    "financialassetsavailableforsale": 2847000,
    "gainslossesonfairvalueonmarketablesecurities": -574000,
    "currentgovernmentgrants": 13000,
    "currentprepaidexpensesother": 82000,
    "otherreceivables": 7000,
    "currentprepaidexpenses": 102000,
    "otherinformationrelatestointangibleasset": "The Company exclusively licensed two families of patents relating to hCDR1: One expires on September 22, 2022 and the other expires on January 14, 2024.",
    "percentageofweightedaveragecostofcapital": 0.21,
    "royaltiesrate": 0.065,
    "percentageofphasesothers": 0.32,
    "tradeandotherpayablestotradesuppliers": 1000,
    "accruals": 26000,
    "accrualsclassifiedascurrent": 205000,
    "othercurrentpayables": 58000,
    "postemploymentbenefitexpensedefinedcontributionplans": 6000,
    "descriptionofwarrantsexercisable": "The warrants shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date.",
    "informationabouthowexpectedvolatilitywasdeterminedshareoptionsgranted": "If the change in standard deviation for that warrants shifted +/- 5%, the impact on profit or loss would be $162 thousands and $159 thousands, respectively. The higher the standard deviation, the higher the fair value.",
    "numberofsharegrantedoptionsinsharebasedpaymentarrangement": 3800000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingexerciseprice": 0.11,
    "numberofwarrantsoutstanding": 1400000,
    "numberofsharesexercisable": 140000000,
    "warrantsissuancedate": "2017-03-07",
    "warrantsexerciseprice": 2.3,
    "warrantsexpirationdate": "2022-09-06",
    "ordinaryshareparorstatedvaluepershare": 0.047,
    "financeexpenses": 329000,
    "reductionofissuedcapital": 165000,
    "numberofoutstandingshareoptionsinsharebasedpaymentarrangement": 1000000,
    "numberofshareexercisableoptionsinsharebasedpaymentarrangement": 5949998,
    "weightedaverageoutstandingexercisepriceofshareoptionsinsharebasedpaymentarrangement": 0.15,
    "weightedaverageexercisepriceofexercisableshareoptionsinsharebasedpaymentarrangement": 0.16,
    "exercisepriceofshareoptionsoutstanding": 0.15,
    "weightedaverageremainingcontractuallifeofshareoptionsoutstanding": "P6Y1M13D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardweightedaveragegrantdatefairvalue": "2017-08-03",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingvalue": 28000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandinginperioddescription": "33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first anniversary",
    "feesrelatedtoserviceproviders": 35000,
    "wagesandsalaries": 112000,
    "expensefromsharebasedpaymenttransactionswithemployees": 5000,
    "patentsandfees": 135000,
    "directorsremunerationexpense": 132000,
    "travelexpense": 27000,
    "rentandofficemaintenance": 13000,
    "insuranceexpense": 106000,
    "professionalfeesexpense": 262000,
    "otherexpensebynature": 15000,
    "feeandcommissionexpense": 29000,
    "financeexpensesrevaluationofmarketablesecurities": 574000,
    "financecosts": 603000,
    "interestincomeondeposits": 93000,
    "gainonexchangedifferencesontranslationnetoftax": 5000,
    "financeincome": 98000,
    "accountingprofit": -1347000,
    "taxeffectoftaxlosses": -310000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 55000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": -1000,
    "taxeffectfromchangeintaxrate": 256000,
    "applicabletaxrate": 0.23,
    "descriptionofnatureofpotentialincometaxrate": "In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018.",
    "taxeffectofimpairmentofgoodwill": 37000000,
    "benefitspaidorpayable": 290000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 7000,
    "adjustmentsforsharebasedpayments": 5000,
    "employeebenefitsexpense": 302000,
    "numberofemployees": 8,
    "amountspayablerelatedpartytransactions": 19000,
    "proportionofownershipinterestinintercureltd": 0.0194,
    "rentexpense": 13000,
    "optionexercisedinsharebasedpaymentarrangement": 6200000,
    "numberofsharewarrantsexercisedinsharebasedpaymentarrangement": 264222220
  }
]